Loading
Instil Bio, Inc., a biopharmaceutical company, focuses on identifying and advancing therapeutic opportunities. It seeks to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet medical need. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.
Previous close
$6.56
−$0.34 · -4.93%
After-hours
$6.7705
+$0.2105 · +3.21%
Oct 8, 5:31 PM ET
Regular session · ET · Market data may be delayed.
Instil Bio, Inc., a biopharmaceutical company, focuses on identifying and advancing therapeutic opportunities. It seeks to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet medical need. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.
Day range
Current $6.56
52-week range
Current $6.56
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
32
Expensive
Sentiment
42
Mixed
Risk
57
Elevated Risk
Momentum
25
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Instil Bio, Inc., a biopharmaceutical company, focuses on identifying and advancing therapeutic opportunities. It seeks to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet medical need. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.
Day range
Current $6.56
52-week range
Current $6.56
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 534K USD | — | — | 5.99M USD | — |
| Gross profit | −534K USD | — | — | −5.99M USD | — |
| Research and development | 10M USD | 11.84M USD | 39.6M USD | 141.06M USD | 107.25M USD |
| Selling, general, and administrative | 27.22M USD | 44.21M USD | 47.55M USD | 62.24M USD | 51.31M USD |
| Operating expenses | 52.37M USD | 73.54M USD | 159.17M USD | 200.18M USD | 155.56M USD |
| Interest income | 3.86M USD | 6.99M USD | 8.87M USD | 3.66M USD | 80K USD |
| Interest expense | 5.83M USD | 8.99M USD | 5.21M USD | 1.88M USD | — |
| Depreciation and amortization | 534K USD | 3.61M USD | 4.76M USD | 5.99M USD | 2.75M USD |
| Operating income | −52.91M USD | −73.54M USD | −159.17M USD | −206.17M USD | −155.56M USD |
| Net income | −71.37M USD | −74.14M USD | −156.09M USD | −223.18M USD | −156.79M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$35.00
433.54% upsidePrice history unavailable
High $120Average $35.00Low $2.00Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI905.53K0.00%2.3T USD0.03%$379.56—
Vanguard Extended Market ETFVXF316.49K0.00%95.4B USD0.05%$233.13—
iShares Micro-Cap ETFIWC83.97K0.01%1.32B USD0.60%$182.79—
Avantis U.S. Small Cap Equity ETFAVSC51.69K—3.04B USD0.25%$69.96—
Dimensional - US Small Cap ETFDFAS45.91K0.00%33.66B USD0.31%$78.10—
Dimensional - US Core Equity 2 ETFDFAC9.56K0.00%88.28B USD0.21%$45.11—
U.S. Core Equity 1 Portfolio ETF Class SharesDCOR7.26K0.00%45.43B USD0.17%$84.07—
Dimensional - US Sustainability Core 1 ETFDFSU6.9K0.00%2.38B USD0.15%$47.88—Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCAvantis U.S. Small Cap Equity ETFAVSCDimensional - US Small Cap ETFDFASDimensional - US Core Equity 2 ETFDFACU.S. Core Equity 1 Portfolio ETF Class SharesDCORDimensional - US Sustainability Core 1 ETFDFSUAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
